Clinical trials
PSMA Positive Tumors or Tumor Tissues clinical trials
Below are recruiting psma positive tumors or tumor tissues clinical trials, each written for real people, not researchers. We’re tracking 1,318 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07459998RecruitingPhase 1/Phase 2
SKB103 study for advanced solid tumors
This trial tests a new drug called SKB103 for people with advanced solid tumors that have not responded to standard treatments or who cannot tolerate them. The study aims to see if SKB103 is safe and effective.
Harbin, HeilongjiangAges 18–75 - NCT06130553RecruitingPhase 1/Phase 2
Study of AZD3470 for patients with MTAP-deficient advanced solid tumors
This trial tests an investigational drug called AZD3470, which blocks a protein called PRMT5, in people whose tumors lack a gene called MTAP. The goal is to see if the drug can shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT06718946RecruitingEarly Phase 1
IV IDOV-SAFE for advanced solid tumors: safety and effect study
This trial tests a new drug called IDOV-SAFE given through a vein. It is for people with advanced solid tumors that have not responded to standard treatments. The study aims to see if the drug is safe and if it can help shrink tumors.
ShanghaiAges 18–75 - NCT07448116RecruitingPhase 1/Phase 2
Testing MCLA-129 plus ensartinib for advanced solid tumors
This trial tests a new two-drug combination (MCLA-129 and ensartinib) for people with advanced solid tumors that have a specific genetic change called MET amplification or overexpression. The goal is to see if this combo can shrink tumors or stop them from growing when other treatments have stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT07112053RecruitingPhase 2
Vaccine with hormone therapy or chemo for advanced breast cancer
This trial tests a vaccine (STEMVAC) given with your standard hormone therapy or chemotherapy. It is for people with advanced hormone receptor-positive, HER2-negative breast cancer who are already on certain treatments. The goal is to see if adding the vaccine can help control the cancer better.
Seattle, WashingtonAges 18 years+ - NCT05101070RecruitingPhase 1/Phase 2
Study of an anti-cancer drug alone or with immunotherapy
This Phase 1/2 study tests a new cancer drug (S-531011) in people with advanced or metastatic solid tumors, either by itself or combined with an immunotherapy drug. It may help shrink tumors and learn how the treatment works, but it also requires extra procedures like repeat tumor biopsies and frequent monitoring.
Los Angeles, CaliforniaAges 18 years+ - NCT07055594RecruitingPhase 1/Phase 2
Study of SOA101 for advanced solid tumors
This trial tests a new drug called SOA101 for people with certain advanced cancers that have stopped responding to standard treatments. It aims to see if the drug is safe and if it can help shrink tumors.
TaichungAges 18 years+ - NCT05839275RecruitingPhase 1/Phase 2
Radiation plus two medicines for high-risk soft tissue sarcoma
This Phase 1/2 trial tests whether combining radiation with two targeted/immune medicines can shrink or control high-risk soft tissue sarcoma and improve outcomes. It may help patients whose tumors are large, hard to fully remove, or have come back after prior treatment.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07093970RecruitingPhase 1/Phase 2
MRG006A for advanced solid tumors
This trial tests a new drug, MRG006A, for people with advanced solid tumors, especially liver cancer. It aims to see if the drug is safe and effective by targeting a protein called GPC3 found on some cancer cells.
Beijing, Beijing MunicipalityAges 17–85 - NCT06062927Recruiting
Genes and scans predict response to immunotherapy and targeted therapy for advanced sarcoma
This trial is testing whether a combination of two drugs—a targeted therapy (surufatinib) and an immunotherapy (envafolimab)—can help people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery. Researchers will also use a person's genetic information and scans to see if they can predict who will benefit the most.
Beijing, Beijing MunicipalityAges 18–75 - NCT07382531RecruitingPhase 1/Phase 2
OH2 and BS006 injection for advanced solid tumors
This trial tests a combination of two injections, OH2 and BS006, for people with advanced solid tumors that have not responded to standard treatments. The injections are given directly into the tumor, aiming to shrink or control the cancer.
Wuhan, HubeiAges 18–75 - NCT07377591RecruitingPhase 1
Study of HDM2006 for advanced solid tumors
This trial tests a new drug called HDM2006 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
ShanghaiAges 18 years+ - NCT06995105RecruitingPhase 1/Phase 2
Personalized mRNA Vaccine for Advanced Liver Cancer
This trial tests a personalized mRNA vaccine made from your tumor's unique genetic markers. It is for people with advanced liver cancer who have not yet received any treatment.
Hangzhou, ZhejiangAges 18–75 - NCT06397963Recruiting
Personalized immune cell therapy for advanced solid tumors
This study tests a new treatment using your body's own immune cells (called tumor-infiltrating lymphocytes) that are taken from your tumor, grown in a lab, and then put back into you. It's for people with advanced solid tumors who have run out of standard options.
Beijing, Beijing MunicipalityAges 18–70 - NCT06644300RecruitingPhase 1
Study of BM230 for advanced solid tumors with HER2
This trial tests a new drug called BM230 for people with advanced solid tumors that have HER2 protein or gene changes. It aims to see if the drug is safe and effective for those who have run out of standard treatment options.
Brisbane, QueenslandAges 18 years+ - NCT06404281RecruitingPhase 1
Modified immune cells for advanced solid tumors
This trial tests a new type of immune cell therapy (gamma-delta T cells that have been modified to target PD-1) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if these cells can help your immune system fight the cancer.
ChangzhouAges 18–80 - NCT07077434RecruitingPhase 1
Study of Navlimetostat for advanced solid tumors with specific gene change
This trial tests a new drug, Navlimetostat (BMS-986504), for people with advanced solid tumors that have a specific genetic change called MTAP deletion or loss. It looks at safety, side effects, and how the drug works in the body.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06410131RecruitingPhase 1
Safety study of FTL008.16 for advanced solid tumors
This trial tests an investigational drug called FTL008.16 for people with advanced solid tumors that may carry a protein called 5T4. The main goal is to see if the drug is safe and tolerable.
Beijing, Beijing MunicipalityAges 18–75 - NCT07134998RecruitingPhase 1
Study of HRS-6093 for advanced solid tumors with KRAS G12D mutation
This trial tests a new drug, HRS-6093, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and effective for those who have not responded to or cannot tolerate other treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06088472RecruitingPhase 1
TIL therapy for advanced solid tumors
This trial tests a treatment made from your own immune cells (TILs) that are taken from a tumor, grown in a lab, and then given back to you to fight cancer. It's for people with solid tumors that have spread or come back after treatment.
Xuzhou, JiangsuAges 18–70 - NCT07004296RecruitingPhase 1
Study of HDM2005 for advanced solid tumors
This trial tests a new drug, HDM2005, in people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective for tumors that show a specific marker called ROR1.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06682117Recruiting
A study of a personalized vaccine for advanced solid tumors
This trial tests a personalized vaccine made from your own cells to help your immune system attack tumor-specific targets. It may be an option if standard treatments have stopped working or caused side effects you can't tolerate.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06248697RecruitingEarly Phase 1
CAR-T cells targeting MSLN with PD-1/CTLA-4 blockers for advanced solid tumors
This trial tests a new type of immune cell therapy (CAR-T cells) that target a protein called MSLN on cancer cells, and also release a special antibody to block two other proteins (PD-1 and CTLA-4) that cancers use to hide from the immune system. It is for people with advanced solid tumors like non-small-cell lung cancer or mesothelioma who have not responded to standard treatments.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06646952Recruiting
PET imaging of solid tumors with a CD147-targeting probe
This trial tests a special imaging agent (a nanobody probe) that targets a protein called CD147 on tumor cells. If you have a solid tumor like melanoma, liver, colorectal, pancreatic, breast, stomach, or lung cancer, the PET scan may help doctors see your cancer more clearly.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new PSMA Positive Tumors or Tumor Tissues trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for psma positive tumors or tumor tissues?
- Yes. Clin2 currently lists 1,318 recruiting psma positive tumors or tumor tissues studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a psma positive tumors or tumor tissues trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a psma positive tumors or tumor tissues trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.